HIF1A and breast cancer: These types of tumors are highly vascularised and harbor hypoxic regions and disorganized vasculature: Sunitinib and sorafenib—small molecule inhibitors targeting the HIF-1-target gene VEGF—are currently in clinical trials for use in advanced breast cancer to hamper cell dissemination, but the access of these inhibitors to the bone marrow seems incomplete with the present administration routes [45].